ATE238792T1 - Verwendung von makroliden zur behandlung von glaukom - Google Patents

Verwendung von makroliden zur behandlung von glaukom

Info

Publication number
ATE238792T1
ATE238792T1 AT99905206T AT99905206T ATE238792T1 AT E238792 T1 ATE238792 T1 AT E238792T1 AT 99905206 T AT99905206 T AT 99905206T AT 99905206 T AT99905206 T AT 99905206T AT E238792 T1 ATE238792 T1 AT E238792T1
Authority
AT
Austria
Prior art keywords
macrolids
treat glaucoma
compounds
glaucoma
treat
Prior art date
Application number
AT99905206T
Other languages
English (en)
Inventor
Shozo Sakuma
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPP1955A external-priority patent/AUPP195598A0/en
Priority claimed from AUPP2992A external-priority patent/AUPP299298A0/en
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Application granted granted Critical
Publication of ATE238792T1 publication Critical patent/ATE238792T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT99905206T 1998-02-23 1999-02-17 Verwendung von makroliden zur behandlung von glaukom ATE238792T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPP1955A AUPP195598A0 (en) 1998-02-23 1998-02-23 New use
AUPP2992A AUPP299298A0 (en) 1998-04-16 1998-04-16 New use
PCT/JP1999/000681 WO1999042104A1 (en) 1998-02-23 1999-02-17 Use of macrolide compounds for treating glaucoma

Publications (1)

Publication Number Publication Date
ATE238792T1 true ATE238792T1 (de) 2003-05-15

Family

ID=25645716

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99905206T ATE238792T1 (de) 1998-02-23 1999-02-17 Verwendung von makroliden zur behandlung von glaukom

Country Status (9)

Country Link
US (1) US6384073B1 (de)
EP (1) EP1056454B1 (de)
JP (1) JP2002503692A (de)
AT (1) ATE238792T1 (de)
DE (1) DE69907418T2 (de)
DK (1) DK1056454T3 (de)
ES (1) ES2192832T3 (de)
PT (1) PT1056454E (de)
WO (1) WO1999042104A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7265150B1 (en) * 1998-08-14 2007-09-04 Gpi Nil Holdings Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds for vision and memory disorders
US6376517B1 (en) * 1998-08-14 2002-04-23 Gpi Nil Holdings, Inc. Pipecolic acid derivatives for vision and memory disorders
US7338976B1 (en) * 1998-08-14 2008-03-04 Gpi Nil Holdings, Inc. Heterocyclic esters or amides for vision and memory disorders
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
ES2269206T3 (es) * 1999-11-12 2007-04-01 Alcon, Inc. Ligandos de neurofilina para tratar trastornos oculares.
GB0012383D0 (en) * 2000-05-22 2000-07-12 Novartis Ag Organic compounds
WO2003061519A2 (en) * 2002-01-18 2003-07-31 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
EP1904056B1 (de) 2005-07-18 2009-04-29 Minu, L.L.C. Verwendung von Makroliden zur Wiederherstellung der Kornealempfindungen
US7592330B2 (en) * 2005-08-08 2009-09-22 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
JP2009514969A (ja) 2005-11-09 2009-04-09 コンビナトアールエックス インコーポレーティッド 医学的状態を治療するための方法、組成物、およびキット
AU2007305423A1 (en) 2006-09-28 2008-04-10 Follica, Inc. Methods, kits, and compositions for generating new hair follicles and growing hair
CA2673863A1 (en) * 2006-12-28 2008-07-10 Limerick Biopharma, Inc. Methods and compositions for therapeutic treatment
US9044391B2 (en) * 2007-01-10 2015-06-02 Board Of Regents, The University Of Texas System Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery
MX2010001141A (es) * 2007-07-31 2010-03-01 Limerick Biopharma Inc Analogos fosforiladosde pirona y metodos.
US20100092479A1 (en) * 2008-08-18 2010-04-15 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
US20110130711A1 (en) * 2009-11-19 2011-06-02 Follica, Inc. Hair growth treatment
US20140147413A1 (en) * 2011-02-28 2014-05-29 Dong Feng Chen Therapies That Target Autoimmunity For Treating Glaucoma And Optic Neuropathy
EP3094314B1 (de) 2014-01-16 2021-06-23 MUSC Foundation For Research Development Gezielte nanoträger zur verabreichung von immunsuppressiva

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
CA2054983A1 (en) * 1990-11-08 1992-05-09 Sotoo Asakura Suspendible composition and process for preparing the same
JP3158437B2 (ja) * 1991-04-26 2001-04-23 藤沢薬品工業株式会社 眼疾患に対するマクロライド化合物の使用
ZA924953B (en) * 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
US5922773A (en) * 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
WO1997031020A1 (en) * 1996-02-22 1997-08-28 The General Hospital Corporation METHODS AND COMPOSITIONS FOR ENHANCING CELLULAR RESPONSE TO TGF-β LIGANDS
US5994388A (en) * 1997-03-18 1999-11-30 The Children's Medical Center Corporation Cytochalasin and isoindolinone derivatives as inhibitors of angiogenesis

Also Published As

Publication number Publication date
EP1056454B1 (de) 2003-05-02
DE69907418T2 (de) 2003-11-13
WO1999042104A1 (en) 1999-08-26
DK1056454T3 (da) 2003-08-18
PT1056454E (pt) 2003-08-29
JP2002503692A (ja) 2002-02-05
US6384073B1 (en) 2002-05-07
DE69907418D1 (de) 2003-06-05
EP1056454A1 (de) 2000-12-06
ES2192832T3 (es) 2003-10-16

Similar Documents

Publication Publication Date Title
ATE238792T1 (de) Verwendung von makroliden zur behandlung von glaukom
ID21526A (id) 4-hidroksiquinolin-3-karboksamida dan hidrazida sebagai bahan anti-virus
DE59409312D1 (de) Imidazopyridine und ihre anwendung zur behandlung von magen-darm krankheiten
DE69521620D1 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DE60236413D1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
ATE254461T1 (de) Behandlung von augenschmerzen
DE59409832D1 (de) Pflaster zur behandlung von nagelmykosen
DE60019473D1 (de) (S,S)-Reboxetin zur Behandlung von peripheren Neuropathien
ATE198708T1 (de) Verwendung von makrolid-verbindungen gegen augenerkrankungen
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
ATE321548T1 (de) Verwendung von statin zur behandlung von hauterkrankungen
RU95111308A (ru) Производные 2-амино-4-фенил-4-оксомасляной кислоты, способы получения, фармацевтическая композиция
DE60008143D1 (de) Lipoxin-a4 und deren analoge zur behandlung von trockenen augen
ATE201992T1 (de) Carbostyrilderivat zur behandlung von ophthalmologischen erkrankungen
ATE271390T1 (de) Verwendung von azithromycin zur topischen behandlung von augeninfektionen
DE69918972D1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
DE60018704D1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
ATE296635T1 (de) Pharmazeutische zusammenstellung zur vorbeugung und behandlung von mit zellkrankheiten des augenhintergrundes zusammenhängenden krankheiten
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
DE69917074D1 (de) Optisch aktives pyridyl-4h-1,2,4-oxadiazinderivat und seine verwendung zur behandlung von gefässkrankheiten
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
ATE244008T1 (de) Verwendung von makroliden zur behandlung von akuten lungenverletzungen
ATE209914T1 (de) Verwendung von pyridylmethylsulfinyl-1h- benzimidazol derivaten zur behandlung durch helicobacter verursachter erkrankungen
DE60034110D1 (de) Verwendung von 4-aminopyridin zur behandlung von peripheren neuropathien

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1056454

Country of ref document: EP

REN Ceased due to non-payment of the annual fee